** Shares of drugmaker BioMarin Pharmaceutical BMRN.O rise 10.5% to $72.51 premarket
** Co, after market close on Wednesday, reported Q4 rev. of $747 mln, beating estimate of $713.4 mln, as per data compiled by LSEG
** Reported Q4 adj. profit of 92 cents per share vs estimate of 53 cents per share
** Forecast 2025 adj. profit in the range of $4.20 to $4.40 per share, above estimate of $3.26 per share
** Brokerage Evercore ISI says BMRN's Q4 results are "solid"; adds "it looks like investors may be willing to reward the company for solid execution after all. This was indeed an encouraging update on multiple fronts"
** Stock had fallen 31.8% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.